Introduction to Clinical Trials

Definition:
Clinical trials are systematic studies of new drugs in humans to assess their safety, efficacy, pharmacokinetics, pharmacodynamics, and adverse effects.

Participation

• Participants may gain early access to new treatments and contribute to medical research.
• Inclusion/Exclusion Criteria decide eligibility based on factors like age, gender, disease stage, medical history, and prior treatments.
• These criteria ensure reliable results and participant safety, not personal rejection.
• Trials may involve patients with specific illnesses or healthy volunteers.

Process

• Varies by type of trial.
• Conducted by a team of doctors, nurses, social workers, and other healthcare professionals.

Clinical Trials – Summary Notes

Process

• Health of participants is checked before the trial.
• Participants receive instructions, are closely monitored during the trial, and followed up after completion.
• Success depends on adherence to protocol and regular contact with the research team.

Informed Consent

• Ongoing process of providing trial information before and during participation.
• Doctors/nurses explain study details; translation provided if needed.
• Consent form covers purpose, duration, procedures, and contacts.
• Not a contract – participants may withdraw anytime.

Benefits

• Active role in personal health care.
• Early access to new treatments.
• Expert medical care during trial.
• Contribute to advancement of medical research.

Safety

• Governed by medical ethics and legal codes.
• Federally regulated with safeguards for participant protection.

Clinical Trials – Key Points

Protocol & Reporting

• Trials follow a strict study plan (protocol).
• Results shared in journals, meetings, and with agencies; participant identities remain confidential.

Information for Subjects

Before joining, participants should ask about:

• Purpose, eligibility, prior testing of treatment.
• Tests/procedures involved.
• Risks, benefits vs. current treatment.
• Impact on daily life, duration, need for hospitalization.
• Costs and who pays.
• Who will manage care.

Ideas for Clinical Trials

• Origin: Researchers → lab studies → animal studies → human trials.
• Goal: Evaluate safety, risks, and effectiveness of new treatments.

Do you want me to merge all your sections (Intro, Process, Consent, Benefits, Safety, Protocol, etc.) into one complete concise “exam notes” document?

Here’s a brief version of your notes:

Types & Phases of Clinical Trials

Types of Clinical Trials

1. Treatment Trials – Test new drugs, combinations, surgeries, or radiation.
2. Prevention Trials – Find ways to prevent diseases or recurrence (drugs, vaccines, lifestyle).
3. Diagnostic Trials – Develop better diagnostic tests/procedures.
4. Screening Trials – Improve detection of diseases/conditions.
5. Quality of Life (Supportive Care) Trials – Enhance comfort and well-being of chronic illness patients.

Phases of Clinical Trials

• Phase I (20–80 people): Safety, dosage, side effects.
• Phase II (100–300 people): Effectiveness + safety.
• Phase III (1000–3000 people): Confirm effectiveness, compare with standard treatment, monitor adverse effects.
• Phase IV (Post-marketing): Long-term risks, benefits, and optimal use.

Expanded Access Protocol (Treatment IND)

• Allows patients (not eligible for trials) with life-threatening diseases to access investigational drugs.
• Provides treatment + additional safety data.
• Allowed only if ongoing/completed controlled trials show potential benefit without unreasonable risk.

⭐ Requirements for Conducting Clinical Trials as per Schedule Y

(Complete, combined, easy-to-remember notes)

1️⃣ Pre-Requisites Before Starting a Clinical Trial

Before enrolling any participant, THREE requirements must be fulfilled:

1. DCGI (Drugs Controller General of India) Permission

• Mandatory regulatory approval under Schedule Y / NDCTR.
• Application through Forms CT-18 + CT-21 or CT-04, with prescribed fee.
• Must include all required scientific data.

2. Ethics Committee (EC) Approval

• Study must be approved by EC of each site.
• EC must be registered with DCGI (validity: 3 years).
• No trial can begin without EC approval.

3. CTRI Registration

• Mandatory prospective registration on
  Clinical Trials Registry of India (CTRI) before enrolling first participant.

2️⃣ Application Requirements (What Sponsor Must Submit)

The application to DCGI must include:

A. Chemical & Pharmaceutical Information

• Drug composition
• Manufacturing process
• Stability data
• CMC (Chemistry, Manufacturing & Controls)

B. Preclinical / Animal Data

• Animal pharmacology
• Animal toxicology (acute, subacute, chronic)
• Reproduction toxicity
• Genotoxicity
• Carcinogenicity (if needed)

C. Clinical Data

• Previous human trial data
• Safety and efficacy details
• Published and unpublished evidence

D. Regulatory Information

• Approval status in other countries
• Investigational status abroad

3️⃣ Compliance Requirements (How Trials Must Be Conducted)

Trials must follow:

✔ Approved protocol only
✔ Schedule Y guidelines
✔ Good Clinical Practice (GCP) guidelines
✔ New Drugs & Clinical Trials Rules (NDCTR)
✔ All amendments issued by CDSCO

Changes in protocol require prior approval from EC and DCGI.

4️⃣ Responsibilities of Ethics Committee

• Protect rights, safety, and wellbeing of participants
• Review and approve:
• Protocol
• Informed consent documents
• Compensation rules
• Conduct continuing review
• Report serious violations to DCGI

EC must be independent and DCGI-registered.

5️⃣ Informed Consent Requirements

Schedule Y mandates:

• Written informed consent from each participant
• Language understandable to the subject
• Clear statements on:
• Free medical management for trial-related injury
• Financial compensation for injury or death
• Investigators must give a copy of signed consent to the participant/attendant
• Audio–video recording mandatory for vulnerable participants

6️⃣ Safety Reporting Requirements (SAEs)

Investigators must report Serious Adverse Events (SAEs), including death:

• To DCGI, Sponsor, and Ethics Committee
  ➡ within 24 hours (initial report)
• Detailed, causality-assessed report
  ➡ within 10 calendar days

Sponsor, investigator, and EC share responsibility for timely reporting.

7️⃣ Conduct of Trial – Operational Requirements

• Qualified investigator with adequate experience
• Adequate site facilities (emergency care, labs, equipment)
• IP (Investigational Product) must meet GMP standards
• Record keeping must follow GCP
• Monitoring and audits must be performed regularly
• Maintain:
• CRFs
• Source documents
• Drug accountability logs
• EC & DCGI correspondence

Documents must be archived for minimum 5 years after study completion.

8️⃣ Compensation & Medical Management

Schedule Y + Rule 122DAB require:

• Free medical care for injury during the study
• Financial compensation for:
• Trial-related injury
• Death
• Permanent disability
• Congenital anomalies
• Sponsor must provide timely compensation after causality assessment.

9️⃣ Trial Registration & Reporting

• All clinical trials must be registered in CTRI
• Final study report must be submitted to DCGI and EC
• Summary results must be made publicly accessible as per CTRI norms

⭐ Super-Short Revision Notes

Schedule Y requires:

1. DCGI approval + EC approval + CTRI registration
2. Submission of chemical, preclinical, clinical & regulatory data
3. Compliance with Schedule Y + GCP + NDCTR
4. DCGI-registered Ethics Committee review
5. Detailed informed consent (copy to participant)
6. SAE reporting in 24 hours, full report in 10 days
7. Proper trial conduct, monitoring & documentation
8. Compensation & medical management for injuries
9. Final report + document archiving for 5 years

🧑‍⚕️ Inclusion and Exclusion Criteria in Clinical Trials

✅ What are Inclusion and Exclusion Criteria?

They are pre-defined rules describing who can participate and who cannot participate in a clinical trial.

These criteria ensure:

• Safety of participants
• Scientific validity
• Homogeneous (similar) study population
• Reduction of bias

✅ Inclusion Criteria (Who CAN participate?)

Definition

Inclusion criteria are the essential characteristics that a person must have to join the clinical trial.

Purpose

• Ensure subjects have the condition being studied
• Ensure correct age, gender, disease severity, and baseline health
• Increase accuracy and relevance of results

Examples

For a Type 2 Diabetes trial:

• Age 30–65 years
• Diagnosed with Type 2 diabetes for ≥ 6 months
• HbA1c between 7–10%
• BMI 25–40
• Willing to give informed consent

For a vaccine trial:

• Healthy adults 18–55 years
• No prior COVID-19 infection
• No vaccination in last 4 weeks

🚫 Exclusion Criteria (Who CANNOT participate?)

Definition

Exclusion criteria are conditions or factors that disqualify a person from participating due to safety concerns or to avoid confounding results.

Purpose

• Prevent harm to participants
• Eliminate factors that may interfere with the study
• Reduce risk
• Control variability

Examples

For a Type 2 Diabetes trial:

• Type 1 diabetes
• Severe kidney or liver disease
• Pregnant or breastfeeding
• Taking medications that interact with the study drug
• History of severe hypoglycemia

For a vaccine trial:

• Immunocompromised patients
• Allergy to vaccine components
• Acute fever or infection
• Participation in another trial recently

🔍 Why Are These Criteria Important?

• Ensure safety
• Minimize variability
• Improve validity of results
• Protect vulnerable populations
• Ensure ethical standards
• Meet regulatory requirements (FDA, EMA, CDSCO, ICMR)

⭐ In Simple Words

Inclusion criteria = Who is allowed
Exclusion criteria = Who is not allowed
Both help choose the right participants to get accurate and safe trial results.

 

🟦 Open Label Trial

✅ Definition

An open label trial is a type of clinical trial where both the researcher (investigator) and the participant know which treatment is being given.

➡️ No blinding is used.
➡️ Everyone is aware of the treatment assignment.

🧪 Why Are Open Label Trials Used?

When blinding is not possible:

• Comparing tablet vs surgery
• Comparing lifestyle intervention vs drug
• Using a treatment with unique effects that cannot be hidden

When it is unethical to blind:

• Life-saving treatment
• When placebo cannot be justified

For early-phase trials:

• Phase 1 safety studies often open label
• Dose-finding studies

For post-marketing studies:

• Real-world effectiveness
• Patient-reported outcomes

📌 Characteristics

• No placebo or dummy treatment
• Participants know what they receive
• Investigator also knows
• Can have bias (performance bias, reporting bias)

🩺 Example

Testing a new insulin delivery device:

• All patients are given the new device.
• Both doctor and patient know what device is used.
• Outcomes like glucose control and ease of use are assessed.

➡️ This is an open label trial.

🎯 Advantages

• Easy to conduct
• Less expensive
• Useful when blinding is difficult
• Better for patient compliance
• Real-world setting

⚠️ Disadvantages

• Higher risk of bias
• Performance bias
• Observation bias
• Reporting bias
• Results may be less reliable than blinded trials

⭐ In One Line

An open label trial is a clinical study where both the doctor and the participant know which treatment is being given, with no blinding involved.

 

 

 ✅ Definition of Bias

Bias is a systematic error in

 the design, conduct, or analysis of a study that leads to an incorrect or distorted estimate of a treatment’s true effect.

👉 It is not random; it consistently pushes results in one direction, making them unreliable.

⭐ Key Points to Remember

• Bias causes the study results to differ from the truth
• It can occur at any stage: planning, data collection, analysis, or interpretation
• It reduces validity of the study
• Blinding, randomization, and allocation concealment help reduce bias

✅ Single-Blind Method

Definition

In a single-blind clinical trial, only the participants (subjects) do NOT know which treatment they are receiving.
The researchers/investigators DO know who is receiving which treatment.

Purpose

• To reduce participant bias
  (e.g., placebo effect, expectations affecting response)

Example

A study testing a new painkiller:

• Group A receives the new drug
• Group B receives a placebo
• Participants do not know whether they got the drug or placebo
• But the researcher knows which group each participant is in

This ensures that patient expectations do not influence pain-relief reporting.

✅ Double-Blind Method

Definition

In a double-blind clinical trial, both participants AND the researchers/ investigators do NOT know which participants are getting the test drug or placebo.

Purpose

• To reduce participant bias
• To reduce researcher bias, especially during:
• assessment of outcomes
• observation
• data collection

Example

A vaccine trial:

• Group A receives the new vaccine
• Group B receives a placebo injection
• Both the participants and the researchers assessing the outcomes do not know who received what
• Only an independent data safety monitoring board has the code list

This prevents doctors or participants from being influenced while recording symptoms, side effects, or effectiveness.

🔍 Simple Comparison Table

Feature	Single-Blind	Double-Blind
Participant knows treatment?	❌ No	❌ No
Researcher knows treatment?	✔️ Yes	❌ No
Bias reduced	Participant bias	Participant + researcher bias
Example	Painkiller trial	Vaccine trial

⭐ Quick Tip (Remember easily)

• Single blind → 1 group unaware (participants)
• Double blind → 2 groups unaware (participants + researchers)

Drug Development Process

Drug Development Process – Summary

Introduction:

• Drugs are key therapeutic tools in modern healthcare.
• New drug development is a major focus for pharma research.
• Early drug discoveries were often based on empirical observations (e.g., foxglove for CCF).

Definition:

Drug development is a structured process aimed at creating new, safe, and effective treatments to improve health and quality of life.

Steps in Drug Discovery:

1. Target Selection
2. Lead Identification
3. Lead Optimization
4. Product Development

Target Selection – Key Points:

• Understand the disease and its underlying cause.
• Study the mechanism of disease.
• Supports effective research and development.
• Helps design strategies to slow/reverse disease progression.

Common Drug Targets:

• Receptors
• Proteins
• Enzymes
• DNA

Target Identification:

• Targets: Receptors, proteins, enzymes, DNA, RNA, ribosomes.
• Merthods:
• Classical: Cellular & molecular biology
• Newer: Genomics & proteomics

Target Validation:

• Confirms the target is involved in the disease.
• Ensures the drug binds effectively and shows curative potential.
• Done in in-vitro and in-vivo phases.

Lead Identification:

• Identifies compounds that bind the target protein.
• Sources: Natural (plants, microbes) or compound libraries.
• Hits from screening are retested to confirm activity.

Lead Optimization:

• Chemical structure of "hit" compound is modified.
• Improves drug properties (absorption, metabolism, etc.).
• Produces a preclinical drug candidate.

Studies involved:

• Kinetics, dynamics, absorption, distribution, metabolism, excretion.

Product Development:

• Final formulation of the drug is prepared for testing and manufacturing.

Drug Discovery Approaches:

• Preclinical Testing: Pharmacological and toxicological tests.
• Clinical Testing: IND application, drug characterization, dosage form development.

Preclinical Testing/Evaluation:

• Aim: Assess drug safety and effectiveness before human trials.
• Animal testing is done due to species differences from humans.
• Two major types:
1. Pharmacological testing
2. Toxicological testing

Pharmacological Testing:

• Checks drug effectiveness and safety.
• Includes: a) Selectivity testing
  b) Pharmacological profiling
  c) Animal disease models
  d) Safety pharmacology

Selectivity Testing:

1. Screening: Assesses how specific the drug is to its target.
2. Binding Assays: Measures drug-receptor binding strength.

Pharmacological Profiling:

• Studies pharmacodynamic effects using:
1. In-vitro models: Isolated tissues (e.g., cardiac, smooth muscle)
2. In-vivo models: Whole animal studies (costly and time-consuming)

Animal Models of Disease:

• Used to mimic disease conditions.
• Includes:
1. Acute models
2. Chronic models

Animal Models in Drug Testing:

1. Acute Models:

• Mimic short-term clinical conditions.
• Example: Hot plate test for pain (analgesics).

2. Chronic Models:

• Mimic long-term diseases.
• Example: Opiate self-administration as a model for addiction.

3. Genetic Models:

• Use transgenic animals (with gene modifications) to simulate human diseases.

Safety Pharmacology:

• Evaluates life-threatening effects of a drug unrelated to its main action.
• Focuses on unexpected effects on major organs.
• Detects hazardous or dangerous effects at therapeutic doses.

Levels of Safety Testing:

1. Molecular level
2. Cellular level
3. Whole animal testing

Pharmacological Testing – Levels of Study

1.     Molecular Level

• Assesses drug’s selectivity for receptors and enzyme systems.
• Uses cell membrane fractions from organs/glands.

2.     Cellular Level

• Uses cell/tissue cultures and simulations.
• Tissues: blood vessels, heart, lungs, ileum (rat/guinea pig).

3.     Whole Animal Study

• Evaluates drug effects on organs/disease models (e.g., antihypertensive in rats).
• Ensures no serious unwanted effects.

Toxicological Testing/Evaluation

• All drugs can be toxic at some dose.
• Animal studies necessary despite species variation.
• Determines toxicity for short- and long-term use.

Types of Toxicity Studies

1.     Acute Toxicity (Short-Term)

• Single high-dose test.
• Observed over ~30 days.
• Monitors behavior, body weight, biochemical changes.

2.     Sub-Acute Toxicity

• Daily dosing for ≥2 weeks in 2 species.
• Supports initial human trials.
• Human dose often 1/10th of highest non-toxic animal dose.

3.     Chronic Toxicity

• 3–6 months (or ≥1 year for chronic use drugs).
• Monitors weight, hematology, biochemistry, urine.

4.     Reproductive Studies

• Tests effects on fertility, pregnancy, offspring development.

5.     Carcinogenicity Studies

• Long-term in rodents (mice/rats).
• Monitors tumour incidence, type, site, and survival analysis.

6.     Genotoxicity Studies

• Determine if a drug causes genetic mutations in bacteria or mammalian cells.
• Includes tests like dominant lethal mutation studies.
• In vitro methods are used to reduce animal usage, though they have limited predictive value.

INDA – Investigational New Drug Application

• A formal request to the FDA to begin human testing of a new drug.
• Submitted before starting clinical trials.
• Can be submitted by the sponsor or a CRO (Contract Research Organization).

When INDA is Required:

• Testing a new drug not previously approved.
• Drug not generally recognized as safe/effective under its labelling.

Types of INDs:

1. Investigator IND – Submitted by a physician who initiates and conducts the trial.
2. Commercial IND – Submitted by companies for market approval.
3. Emergency Use IND – For experimental drug use in urgent situations.
4. Treatment IND – For life-threatening conditions when the drug shows promise.

IND Submission Requirements:

1. Animal Pharmacology & Toxicology Data – To assess drug safety in humans.
2. Manufacturing Information – Details of composition, manufacturer, stability, controls.
3. Clinical Protocols & Investigator Details – Ensures proper study design and qualified investigators.

IND Format & Contents:

• Cover Sheet (FDA Form 1571): Sponsor details, phase info, commitments.
• Table of Contents
• Investigator’s Brochure
• Study Protocols & Investigator/IRB Info
• Chemistry, Manufacturing, Control (CMC) Data
• Previous Human Experience (if any)

Outcome of IND Submission:

• If FDA raises no objections within 30 days, clinical trials may begin.
• The Investigator’s Brochure acts as temporary labelling during trials.

DRUG CHARACTERIZATION

1. Biological Characterization

• Assesses drug efficacy and toxicity in biological systems.
• Divided into:
• Biochemical Assays: Receptor binding, enzyme inhibition, metabolism.
• Cellular Assays: Cell culture studies, tissue effects, liver metabolism.
• Whole Animal Assays: LD₅₀, organ toxicity, PK/PD, disease models.

2. Physio-Chemical Characterization

• Determines drug’s physical and chemical properties for formulation.
• Solubility, pKa, partition coefficient
• Stability, chemical structure (NMR, MS, X-ray)
• Impurity analysis (TLC, HPLC, GC)
• Polymorphism

DOSAGE FORMS

Types of Dosage Forms:

1. Tablets & Capsules
2. Injections & Infusions
3. Pessaries & Suppositories
4. Solutions, Suspensions & Elixirs
5. Ointments, Creams & Paints
6. Aerosols & Inhalers
7. Transdermal Patches

Selection Factors:

• Absorption, stability, patient compliance, therapeutic needs.

Examples:

• Tablets unsuitable if drug is acid-sensitive → use injection instead.
• Inhalers deliver drug directly to lungs but need careful dosing.
• Suppositories useful for local effects but have limited general use.
• Transdermal patches offer sustained release but may irritate skin.